MedTrace Logo

Predicting Progression of Developing Myeloma in a High-Risk Screened Population and General Population

NCT05837884 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2026-02-04

No results posted yet for this study

Summary

We will seek consent from participants to use the data and biospecimens collected according study protocol to address additional research questions for MGUS, SMM, MM, and other conditions.

Our overarching hypothesis is that early detection of MGUS/SMM in a high- risk population, along with the comprehensive characterization of genomic/epigenomic and microenvironmental/immune regulators of disease progression will lead to strategies that intercept disease progression and improve survival.

Conditions

  • Healthy

Interventions

DIAGNOSTIC_TEST

blood sampling

Participants will provide a blood sample that will be used to determine whether they have a monoclonal protein

Sponsors & Collaborators

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-05
Primary Completion
2026-06-30
Completion
2028-06-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05837884 on ClinicalTrials.gov